Skip to main content

Featured

More HZMB private car quotas set

The governments of Hong Kong and Macau have agreed to increase the regular quotas for Hong Kong cross-boundary non-commercial private cars using the Hong Kong-Zhuhai-Macao Bridge to Macau, the Transport Department announced today.   The decision was made to enhance traffic flow between Hong Kong and Macau, better utilising the bridge, the department said.   It will increase the Hong Kong quota by 1,000, following the earlier quota allocation of 1,800 for Hong Kong.   The additional quota will be distributed in two phases from the second quarter.   Half of the additional 1,000 quota allocations is for company applicants and the other half is for individual applicants. The quotas are valid for no more than three years. The eligibility criteria of quota applications remains the same.   Private cars allocated with Hong Kong quotas will be permitted to access the city of Macau multiple times using the bridge.   The Hong Kong quota allotments will be re-allocated upon expiry thro

Vaccine recommendations published

The two scientific committees under the Centre for Health Protection convened a meeting today to provide recommendations on the use of COVID-19 vaccination for those with previous COVID-19 infection.   Joined by the Chief Executive’s expert advisory panel, the committees also discussed the existing evidence on COVID-19 vaccine effectiveness against different variants.       The meeting noted that previous COVID-19 infection usually confers immunity for at least six to nine months for the majority of patients. There is accumulating evidence showing that those previously infected with COVID-19 would be further protected by one dose of mRNA vaccines.   After receiving one dose of mRNA vaccine, these people may experience more systemic side effects, such as fatigue, headache, chills, muscle pain, fever and joint pain, when compared to those without prior infection.   People who wish to receive the mRNA vaccine should wait for at least 90 days after discharge from previous infection.   The meeting also noted that in general, studies have shown that the existing vaccines work well against the non-variant. The effectiveness data against variants differ by vaccines.   The Fosun Pharma/BioNTech vaccine is effective against the variants which first emerged in the UK and Brazil, but is less effective against the South African one.   There is currently limited efficacy data of CoronaVac developed by Sinovac Biotech (Hong Kong) against variants.   The vaccine developed by AstraZeneca in collaboration with the University of Oxford is effective against the UK variants but is ineffective against the South African one.   The meeting also agreed that the combination of non-pharmaceutical interventions with vaccination will allow for maximum protection against the virus. There is a need to continue social distancing, good hand hygiene and wearing a mask in public to reduce the risk of transmission.
http://dlvr.it/RvxspP

Popular Posts